Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents.

Files in This Item:

File	Description	Size	Format
	publisher's version	407.23 kB	Adobe PDF	View/Open

Title:	Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents.
Author(s):	Bruggemann, R.J.M. (314325751) Alffenaar, J.W.C. Blijlevens, N.M.A. (277354617) Billaud, E.M. Kosterink, J.G.W. Verweij, P.E. (146020170) Burger, D.M. (119962306)
Publication year:	2009
Document type:	Article / Letter to editor
Journal:	Clinical Infectious Diseases
ISSN:	1058-4838
Volume:	vol. 48
Issue:	iss. 10
Start page:	p. 1441
End page:	p. 1458
Abstract:	There are currently a number of licensed azole antifungal drugs; however; only 4 (namely, fluconazole, itraconazole, posaconazole, and voriconazole) are used frequently in a clinical setting for prophylaxis or treatment of systemic fungal infections. In this article, we review the pharmacokinetic interactions of these azole antifungal drugs with other coadministered agents. We describe these (2-way) interactions and the extent to which metabolic pathways and/or other supposed mechanisms are involved in these interactions. This article provides an overview of all published drug-drug interactions in humans (either healthy volunteers or patients), and on the basis of these findings, we have developed recommendations for managing the specific interactions.
Subject:	N4i 2: Invasive mycoses and compromised host N4i 3: Poverty-related infectious diseases NCMLS 1A: Infection and autoimmunity
Organization:	Clinical Pharmacy UMCN Extern Haematology Medical Microbiology
Appears in Collections:	Academic bibliography

Please use this identifier to cite or link to this item: http://hdl.handle.net/2066/79688